

ENZO BIOCHEM INC  
Form 8-K  
July 18, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **July 18, 2018**

**Enzo Biochem, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New York**

(State or Other Jurisdiction of Incorporation)

**001-09974**                      **13-2866202**  
(Commission File Number) (IRS Employer Identification No.)

**527 Madison Avenue**



**Item 8.01 Other events**

On July 18, 2018, Enzo Biochem, Inc. (the “Company”) issued a press release titled “Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers and Their Progression, Especially in Women’s Health Area”.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press Release of Enzo Biochem, Inc., dated July 18, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: July 18, 2018 By: /s/ Barry W. Weiner  
Barry W. Weiner  
President